Targeting aurora kinases as therapy in multiple myeloma

Blood

Volumn 109, Issue 9, 2007, Pages 3915-3921

  Shi, Yijiang ^a   Reiman, Tony ^c   Li, Weiqun ^b   Maxwell, Christopher A ^c   Sen, Subrata ^d   Pilarski, Linda ^c   Daniels, Tracy R ^a   Penichet, Manuel L ^a   Feldman, Rick ^e   Lichtenstein, Alan ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Origene Technologies   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BAYER AG   (Germany)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; BORTEZOMIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 34247393658     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-037671     Document Type: Article

References (30)

1. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol. 2003;15:672-683.
2. Katayama H., Brinkley WR, Sen S. The Aurora kinases: Role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22:451-464.
3. Ewart-Toland A, Briassoului P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor susceptibility gene in mouse and human. Nat Genetics. 2003;34:403-412.
4. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 2003;114:585-598.
5. Dutertre S, Descamps S, Prigent C. On the role of aurora-A in centrosome function. Oncogene. 2002;21:6175-6183.
6. Zhou H, Kuang J, Zhong L, et al. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genetics. 1998;20:189-193.
7. Carvalho A, Carmena M, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci. 2003;116:2987-2998.
8. Katayama H. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst. 1999;91:1160-1162.
9. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:2899-2905.
10. Murata-Hori M, Wang YL. The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Current Biol. 2002;12:894-899.
11. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad 2 and Cemp-2 to kinetochores. J Cell Biol. 2003;161:267-280.
12. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262-267.
13. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
14. Castedo C, Perfettini J-L, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Onocogene. 2004;23:2825-2837.
15. Billadeau, D, Jelinek D, Shah, N, LeBien T, Van Ness B. Introduction of an activated N-ras oncogene alters growth characteristics of the IL-6-dependent Myeloma cell lines ANBL-6. Cancer Res. 1995;55:3640-3646.
16. Shi Y, Yan H, Gera J, Lichtenstein A. MTOR inhibitors activate the AKT kinase in myeloma cells by upregulating the IGF receptor/IRS-1/PI3-kinase cascade. Mol Cancer Ther. 2005;4:1533-1540.
17. Yan H, Frost P, Shi Y, et al. Mechanism by which mTOR inhibitors sensitize myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006;66:2305-2313.
18. Katayama H, Zhou H, Tatsuka M, Sen S. Interaction and feedback regulation between STK15/BTAK/Aurora A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem. 2001;276:46219-46224.
19. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in muletiple myeloma and maintains mitotic integrity. Cancer Res. 2005;65:850-860.
20. Hu L, Shi Y, Hsu J-h, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101:3126-3135.
21. Lichtenstein A, Tu Y, Fady C, Vescio R. IL-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-255.
22. Hardin J, MacLeod S, Grigorieva I, et al. IL-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-3070.
23. Billadeau D, Liu P, Jelinek D, LeBien T, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL-6. Cancer Res. 1997;57:2268-2275.
24. Pascreau G, Arlot-Bonnemains Y, Prigent C. Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res. 2003;5:369-374.
25. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004;104:1151-1158.
26. Anand S, Penrhyn-Lowe S, Venkitaraman A. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003;3:51-62.
27. Koffa MD, Casanova CM, Santarella R, et al. HURP (hepatocarcinoma upregulated) is part of a Ran dependent complex involved in spindle. Curr Biol. 2006;16:743-754.
28. Sillje HHW, Nagel S, Korner R, et al. HURP is a Ran importin beta regulated protein that stabilizes kinetochore microtubules in the vicinity of chromosomes. 2006;16:731-742.
29. Yang B, Zhang L, Turley EA. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J Biol Chem. 1993;268:8617-8623.
30. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell. 2003;14:2262-2276.